Rich Insights into the Systemic Lupus Erythematosus Market, Epidemiology Segmentation, Pipeline therapies and Major Players in the Industry
DelveInsight’s “Systemic Lupus Erythematosus (SLE)“ report delivers an in-depth understanding of the Systemic Lupus Erythematosus, historical and forecasted epidemiology as well as the Systemic Lupus Erythematosus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Key Highlights from the Systemic Lupus Erythematosus Market Report:
To learn more, request for Sample@ Systemic Lupus Erythematosus Market Insights
The Systemic Lupus Erythematosus market report offers available therapies, treatment landscape, emerging therapies, changing market landscape, individual market share of pipeline therapies, SLE market drivers, and market barriers, SLE market size during the study period 2017-30 in the 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France), and Japan).
Systemic Lupus Erythematosus: Disease Overview
Systemic Lupus Erythematosus is a chronic inflammatory condition that affects connective tissues such as cartilage and the lining of blood vessels, which provide strength and flexibility to body structures. SLE affects multiple organs and structures, including the skin, joints, kidneys, lungs, central nervous system, and blood-forming (hematopoietic) system, and the signs and symptoms differ from person to person. SLE is one of a wide number of autoimmune disorders, which occur when the body’s immune system attacks its own tissues and organs.
Lupus flares range in severity from moderate to severe. SLE is most prevalent in women of reproductive age (often beginning at childbearing age), though lupus is becoming more widely recognised after the age of 40, particularly among Europeans.
Systemic Lupus Erythematosus Epidemiology Segmentation
The Systemic Lupus Erythematosus report proffers epidemiological analysis for the study period 2017-30 in the 7MM segmented into:
For more information about epidemiology visit, Systemic Lupus Erythematosus Epidemiology
Systemic Lupus Erythematosus Treatment Landscape
The current market of SLE is majorly driven by Corticosteroids, Immunosuppressant, Antimalarials (Plaquenil) and Biologics (Rituximab, Belimumab). Nonsteroidal anti-inflammatory drugs (NSAIDs).
Hydroxychloroquine (Plaquenil) and Belimumab (Benlysta) are approved therapies for the treatment of SLE. With the approval of these therapies, the outlook for patients SLE improved from a 4-year survival rate of ~50% in 1950 to a 15-year survival rate of ~85% by 2013. New biologics targeting B cells, T cells or cytokines (especially interferon) are still going through trials raising the hope that novel therapies for patients with refractory SLE may be available soon.
Systemic Lupus Erythematosus Pipeline Therapies and Major Players
Know more about the SLE Market and Pipeline Therapies @ SLE Market and Emerging Drug Therapies
Systemic Lupus Erythematosus Market Drivers
Systemic Lupus Erythematosus Market Barriers
Scope for the Report
Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France) and Japan)
Study Period: 2017-30
Key Companies: AstraZeneca, ImmuPharma, Eli Lilly, ILTOO Pharma, Biogen, Amgen, UCB Pharma, Neovacs, Idorsia Pharmaceuticals, Boston Pharmaceuticals, Bristol-Myers Squibb, Xencor, among others.
Key SLE Pipeline Therapies: Anifrolumab (AstraZeneca), Lupuzor (ImmuPharma), Baricitinib (Eli Lilly), ILT-101 (ILTOO Pharma), BIIB059 (Biogen), Efavaleukin alfa (Amgen), Dapirolizumab pegol (UCB Pharma/Biogen), IFNα Kinoid (Neovacs), Cenerimod (Idorsia Pharmaceuticals), Avizakimab (Boston Pharmaceuticals), Lulizumab pegol , Iberdomide (Bristol-Myers Squibb), XmAb5871 (Xencor), and others.
SLE Market Segmentation: By Geography, By SLE therapies
Analysis: Comparative and conjoint analysis of SLE emerging therapies
Tools Used: SWOT Analysis
For more details visit @ Systemic Lupus Erythematosus Market
Table of Contents
|4.||Epidemiology and Market Methodology|
|5.||Systemic lupus erythematosus (SLE): Market Overview at a Glance|
|7.||Epidemiology and Patient Population|
|8.||Country Wise-Epidemiology of Prosthetic Joint Infection|
|12.||Systemic lupus erythematosus (SLE): 7 Major Market Analysis|
|13.||SLE: Seven Major Market Outlook|
|14.||SLE Market Drivers|
|15.||Systemic lupus erythematosus Market Barriers|
Get in touch with our Business executive for Pharma and Healthcare Market Assessment and Consulting
Get comprehensive historical and forecast analysis of Systemic Inflammatory Response Syndrome Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as GlaxoSmithKline, AstraZeneca ,CytoSorbents Corporation, Cardinal Health, Asahi Kasei, ConvaTec, CHIESI Farmaceutici, Smith & Nephew, and Orion Corporation among others.
Get comprehensive historical and forecast analysis of Systemic Mastocytosis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Mylan NV, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Johnson & Johnson, Novartis AG, Bayer AG, Mallinckrodt Pharmaceuticals, EPI Health, LLC, and Kaleo Inc.
Get comprehensive historical and forecast analysis of Systemic Scleroderma Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Boehringer Ingelheim International GmbH, Gilead Sciences Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Bayer AG.
DelveInsight’s “Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) – Market Insights, Epidemiology and Market Forecast-2030” report.
DelveInsight’s “Diffuse cutaneous systemic sclerosis (dcSSc) – Market Insights, Epidemiology, and Market Forecast-2030” report.
DelveInsight’s “Systemic Juvenile Idiopathic Arthritis (SJIA) – Market Insights, Epidemiology, and Market Forecast-2030” report.
Get comprehensive historical and forecast analysis of Gene and Cell Therapies Targeting CNS Disorders Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Novartis, Helixmith, BrainStorm Cell Therapeutics, Corestem, Ferrer Internacional others.
DelveInsight’s “Acute Kidney Injury (AKI) – Market Insights, Epidemiology, and Market Forecast-2030” report.
DelveInsight’s “Acute Renal Failure (ARF) (Acute Kidney Injury) – Market Insights, Epidemiology, and Market Forecast-2030” report.
DelveInsight’s “Anemia in CKD patients – Market Insights, Epidemiology, and Market Forecast-2030” report.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at: